Signal management is a critical pillar of pharmacovigilance, aimed at identifying, evaluating, and acting upon new safety information related to medicinal products.

In the European Union, signal detection is performed by the European Medicines Agency (EMA), Member States (MS), and Marketing Authorisation Holders (MAHs), using data from national systems and EudraVigilance, the EU’s central database for adverse drug reactions (ADRs).

Once a signal – a potential new or changing safety risk – is detected, it undergoes a structured process of validation, confirmation, analysis, and assessment to determine the need for regulatory action.

How Signal Management Works in the EU

The Pharmacovigilance Risk Assessment Committee (PRAC) plays a central role in prioritising and assessing validated signals. It issues recommendations, which may include updates to the product’s labelling, requests for further data, or additional safety measures.

The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) ensures that these recommendations are consistently implemented across all EU Member States. If consensus is not reached, the matter can be escalated to the Committee for Medicinal Products for Human Use (CHMP) for a binding resolution.

This harmonised, EU-wide approach ensures that emerging safety concerns are addressed swiftly and effectively, reinforcing public health protection.

Zemir Pharma Consulting's Expertise in Signal Management

At Zemir Pharma Consulting, our dedicated pharmacovigilance team provides full-scope support to MAHs in the EU signal management process, ensuring compliance with regulatory requirements and contributing to patient safety.

We are responsible for:

   - Continuous monitoring and evaluation of safety data related to our clients’ medicinal products

   - Conducting timely and robust signal detection and assessment

   - Analyzing signals and safety data using the EudraVigilance data analysis system (EVDAS)

   - Documenting and reporting safety information in line with EMA and national guidelines

   - Initiating and managing regulatory follow-up actions

   - Coordinating with EU regulatory authorities throughout the signal management lifecycle

Additionally, we support the timely update of Risk Management Plans (RMPs), Product Information, and other safety documentation, and manage communications to healthcare professionals and patients when required.

Partner with Zemir Pharma Consulting for Reliable Pharmacovigilance Services

By choosing Zemir Pharma Consulting, you gain a partner with the expertise, infrastructure, and commitment to ensure your pharmacovigilance obligations are met with accuracy, efficiency, and regulatory integrity.